KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Revenue (2016 - 2025)

Pacific Biosciences Of California has reported Revenue over the past 16 years, most recently at $44.6 million for Q4 2025.

  • Quarterly results put Revenue at $44.6 million for Q4 2025, up 13.82% from a year ago — trailing twelve months through Dec 2025 was $160.0 million (up 3.89% YoY), and the annual figure for FY2025 was $160.0 million, up 3.89%.
  • Revenue for Q4 2025 was $44.6 million at Pacific Biosciences Of California, up from $38.4 million in the prior quarter.
  • Over the last five years, Revenue for PACB hit a ceiling of $58.4 million in Q4 2023 and a floor of $27.4 million in Q4 2022.
  • Median Revenue over the past 5 years was $38.4 million (2025), compared with a mean of $38.9 million.
  • Biggest five-year swings in Revenue: surged 113.35% in 2023 and later tumbled 32.79% in 2024.
  • Pacific Biosciences Of California's Revenue stood at $36.0 million in 2021, then decreased by 24.06% to $27.4 million in 2022, then soared by 113.35% to $58.4 million in 2023, then tumbled by 32.79% to $39.2 million in 2024, then grew by 13.82% to $44.6 million in 2025.
  • The last three reported values for Revenue were $44.6 million (Q4 2025), $38.4 million (Q3 2025), and $39.8 million (Q2 2025) per Business Quant data.